CoChat

Molecular signatures in post-mortem brain tissue of younger individuals at high risk for Alzheimer's disease as based on APOE genotype

Open access
Conejero-Goldberg, C, Hyde, T M, Chen, S, Dreses-Werringloer, U, Herman, M M, Kleinman, J E, Davies, P, Goldberg, T E · 2011 · Molecular Psychiatry
Cited by 53

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Alzheimer's disease (AD) is a neurodegenerative condition characterized histopathologically by neuritic plaques and neurofibrillary tangles. The objective of this transcriptional profiling study was to identify both neurosusceptibility and intrinsic neuroprotective factors at the molecular level, not confounded by the downstream consequences of pathology. We thus studied post-mortem cortical tissue in 28 cases that were non-APOE4 carriers (called the APOE3 group) and 13 cases that were APOE4 carriers. As APOE genotype is the major genetic risk factor for late-onset AD, the former group was at low risk for development of the disease and the latter group was at high risk for the disease. Mean age at death was 42 years and none of the brains had histopathology diagnostic of AD at the time of death. We first derived interregional difference scores in expression between cortical tissue from a region relatively invulnerable to AD (primary somatosensory cortex, BA 1/2/3) and an area known to be susceptible to AD pathology (middle temporal gyrus, BA 21). We then contrasted the magnitude of these interregional differences in between-group comparisons of the APOE3 (low risk) and APOE4 (high risk) genotype groups. We identified 70 transcripts that differed significantly between the groups. These included EGFR, CNTFR, CASP6, GRIA2, CTNNB1, FKBPL, LGALS1 and PSMC5. Using real-time quantitative PCR, we validated these findings. In addition, we found regional differences in the expression of APOE itself. We also identified multiple Kyoto pathways that were disrupted in the APOE4 group, including those involved in mitochondrial function, calcium regulation and cell-cycle reentry. To determine the functional significance of our transcriptional findings, we used bioinformatics pathway analyses to demonstrate that the molecules listed above comprised a network of connections with each other, APOE, and APP and MAPT. Overall, our results indicated that the abnormalities that we observed in single transcripts and in signaling pathways were not the consequences of diagnostic plaque and tangle pathology, but preceded it and thus may be a causative link in the long molecular prodrome that results in clinical AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mp.2010.57

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 17 references

Research works printed but not linked: 52

  1. Haroutunian V, Katsel P, Schmeidler J . Transcriptional vulnerability of brain regions in Alzheimer's disease and dementia. Neurobiol Aging 2007; 30: 561–573. · DOI
  2. Brun A, Gustafson L . Distribution of cerebral degeneration in Alzheimer's disease. A clinico-pathological study. Archiv fur Psychiatrie und Nervenkrankheiten 1976; 223: 15–33. · DOI · Paper page
  3. Reddy PH, McWeeney S . Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models.[see comment]. Neurobiol Aging 2006; 27: 1060–1077. · DOI
  4. Katsel PL, Davis KL, Haroutunian V . Large-scale microarray studies of gene expression in multiple regions of the brain in schizophrenia and Alzheimer's disease. Int Rev Neurobiol 2005; 63: 41–82. · DOI
  5. Mirnics K, Levitt P, Lewis DA . DNA microarray analysis of postmortem brain tissue. Int Rev Neurobiol 2004; 60: 153–181. · DOI
  6. Conejero-Goldberg C, Wang E, Yi C, Goldberg TE, Jones-Brando L, Marincola FM et al. Infectious pathogen detection arrays: viral detection in cell lines and postmortem brain tissue. Biotechniques 2005; 39: 741–751. · doi:10.2144/000112016
  7. Khachaturian ZS . Diagnosis of Alzheimer's disease. Arch Neurol 1985; 42: 1097–1105. · DOI · Paper page
  8. Barnes M, Freudenberg J, Thompson S, Aronow B, Pavlidis P . Experimental comparison and cross-validation of the Affymetrix and Illumina gene expression analysis platforms. Nucleic Acids Res 2005; 33: 5914–5923. · DOI · Paper page
  9. McShane LM, Radmacher MD, Freidlin B, Yu R, Li MC, Simon R . Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data. Bioinformatics 2002; 18: 1462–1469. · DOI · Paper page
  10. LeBlanc AC . The role of apoptotic pathways in Alzheimer's disease neurodegeneration and cell death. Curr Alzheimer Res 2005; 2: 389–402. · DOI · Paper page
  11. Klaiman G, Petzke TL, Hammond J, Leblanc AC . Targets of caspase-6 activity in human neurons and Alzheimer's disease. Mol Cell Proteomics 2008; 7: 1541–1555. · DOI · Paper page
  12. Yasuda RP, Ikonomovic MD, Sheffield R, Rubin RT, Wolfe BB, Armstrong DM . Reduction of AMPA-selective glutamate receptor subunits in the entorhinal cortex of patients with Alzheimer's disease pathology: a biochemical study. Brain Res 1995; 678: 161–167. · DOI · Paper page
  13. Carter TL, Rissman RA, Mishizen-Eberz AJ, Wolfe BB, Hamilton RL, Gandy S et al. Differential preservation of AMPA receptor subunits in the hippocampi of Alzheimer's disease patients according to Braak stage. Exp Neurol 2004; 187: 299–309. · DOI
  14. Altar CA, Vawter MP, Ginsberg SD . Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacol Rev 2009; 34: 18–54. · DOI · Paper page
  15. Zhang YW, Wang R, Liu Q, Zhang H, Liao FF, Xu H . Presenilin/gamma-secretase-dependent processing of beta-amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci USA 2007; 104: 10613–10618. · DOI · Paper page
  16. Repetto E, Yoon IS, Zheng H, Kang DE . Presenilin 1 regulates epidermal growth factor receptor turnover and signaling in the endosomal-lysosomal pathway. J Biol Chem 2007; 282: 31504–31516. · DOI · Paper page
  17. Cha YK, Kim YH, Ahn YH, Koh JY . Epidermal growth factor induces oxidative neuronal injury in cortical culture. J Neurochem 2000; 75: 298–303. · doi:10.1046/j.1471-4159.2000.0750298.x
  18. Kang CB, Hong Y, Dhe-Paganon S, Yoon HS . FKBP family proteins: immunophilins with versatile biological functions. Neurosignals 2008; 16: 318–325. · DOI · Paper page
  19. Hoeffer CA, Tang W, Wong H, Santillan A, Patterson RJ, Martinez LA et al. Removal of FKBP12 enhances mTOR-Raptor interactions, LTP, memory, and perseverative/repetitive behavior. Neuron 2008; 60: 832–845. · DOI · Paper page
  20. Wang HQ, Nakaya Y, Du Z, Yamane T, Shirane M, Kudo T et al. Interaction of presenilins with FKBP38 promotes apoptosis by reducing mitochondrial Bcl-2. Hum Mol Genet 2005; 14: 1889–1902. · DOI · Paper page
  21. Gutman CR, Strittmatter WJ, Weisgraber KH, Matthew WD . Apolipoprotein E binds to and potentiates the biological activity of ciliary neurotrophic factor. J Neurosci 1997; 17: 6114–6121. · DOI · Paper page
  22. Qu HY, Zhang T, Li XL, Zhou JP, Zhao BQ, Li Q et al. Transducible P11-CNTF rescues the learning and memory impairments induced by amyloid-beta peptide in mice. Eur J Pharmacol 2008; 594: 93–100. · DOI
  23. Laity JH, Lee BM, Wright PE . Zinc finger proteins: new insights into structural and functional diversity. Curr Opin Struct Biol 2001; 11: 39–46. · DOI · Paper page
  24. Maguschak KA, Ressler KJ . Beta-catenin is required for memory consolidation. Nature Neurosci 2008; 11: 1319–1326. · DOI · Paper page
  25. Sasaki T, Hirabayashi J, Manya H, Kasai K, Endo T . Galectin-1 induces astrocyte differentiation, which leads to production of brain-derived neurotrophic factor. Glycobiology 2004; 14: 357–363. · DOI
  26. Cooper D, Norling LV, Perretti M . Novel insights into the inhibitory effects of Galectin-1 on neutrophil recruitment under flow. J Leukoc Biol 2008; 83: 1459–1466. · DOI · Paper page
  27. La M, Cao TV, Cerchiaro G, Chilton K, Hirabayashi J, Kasai K et al. A novel biological activity for galectin-1: inhibition of leukocyte-endothelial cell interactions in experimental inflammation. Am J Pathol 2003; 163: 1505–1515. · DOI
  28. Matsuda A, Suzuki Y, Honda G, Muramatsu S, Matsuzaki O, Nagano Y et al. Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Oncogene 2003; 22: 3307–3318. · DOI · Paper page
  29. Zhang JY, Liu SJ, Li HL, Wang JZ . Microtubule-associated protein tau is a substrate of ATP/Mg(2+)-dependent proteasome protease system. J Neural Transm 2005; 112: 547–555. · DOI
  30. Lopez Salon M, Pasquini L, Besio Moreno M, Pasquini JM, Soto E . Relationship between beta-amyloid degradation and the 26S proteasome in neural cells. Exp Neurol 2003; 180: 131–143. · DOI · Paper page
  31. Cecarini V, Bonfili L, Amici M, Angeletti M, Keller JN, Eleuteri AM . Amyloid peptides in different assembly states and related effects on isolated and cellular proteasomes. Brain Res 2008; 1209: 8–18. · DOI
  32. Hoglinger GU, Carrard G, Michel PP, Medja F, Lombes A, Ruberg M et al. Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J Neurochem 2003; 86: 1297–1307. · DOI · Paper page
  33. Stutzmann GE . The pathogenesis of Alzheimer's disease is it a lifelong ‘calciumopathy’? Neuroscientist 2007; 13: 546–559. · DOI · Paper page
  34. LaFerla FM . Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci 2002; 3: 862–872. · DOI · Paper page
  35. Dreses-Werringloer U, Lambert JC, Vingtdeux V, Zhao H, Vais H, Siebert A et al. A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell 2008; 133: 1149–1161. · DOI · Paper page
  36. Mudher A, Lovestone S . Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci 2002; 25: 22–26. · DOI · Paper page
  37. De Strooper B, Annaert W . Where Notch and Wnt signaling meet. The presenilin hub. J Cell Biol 2001; 152: 785–794. · DOI
  38. Herrup K, Arendt T . Re-expression of cell cycle proteins induces neuronal cell death during Alzheimer's disease.[see comment]. J Alzheimers Dis 2002; 4: 243–247. · DOI
  39. Herrup K, Neve R, Ackerman SL, Copani A . Divide and die: cell cycle events as triggers of nerve cell death. J Neurosci 2004; 24: 9232–9239. · DOI · Paper page
  40. Mattson MP, Keller JN, Begley JG . Evidence for synaptic apoptosis. Exp Neurol 1998; 153: 35–48. · DOI · Paper page
  41. Albrecht S, Bourdeau M, Bennett D, Mufson EJ, Bhattacharjee M, LeBlanc AC . Activation of caspase-6 in aging and mild cognitive impairment. Am J Pathol 2007; 170: 1200–1209. · DOI
  42. Zhong N, Scearce-Levie K, Ramaswamy G, Weisgraber KH . Apolipoprotein E4 domain interaction: synaptic and cognitive deficits in mice. Alzheimers Dement 2008; 4: 179–192. · DOI · Paper page
  43. Mahley RW, Huang Y . Apolipoprotein (apo) E4 and Alzheimer's disease: unique conformational and biophysical properties of apoE4 can modulate neuropathology. Acta Neurologica Scandinavica Supplementum 2006; 185: 8–14. · DOI · Paper page
  44. Reddy PH, Beal MF . Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res Rev 2005; 49: 618–632. · DOI · Paper page
  45. Lin MT, Beal MF . Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443: 787–795. · DOI · Paper page
  46. Starkov AA, Beal FM . Portal to Alzheimer's disease.[comment]. Nat Med 2008; 14: 1020–1021. · DOI · Paper page
  47. Smith MA, Drew KL, Nunomura A, Takeda A, Hirai K, Zhu X et al. Amyloid-beta, tau alterations and mitochondrial dysfunction in Alzheimer disease: the chickens or the eggs? Neurochem Int 2002; 40: 527–531. · DOI
  48. Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Pro Natl Acad Sci USA 2009; 106: 20057–20062. · DOI · Paper page
  49. Hardy J, Selkoe DJ . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.[see comment]. [published erratum appears in Science 2002; 297: 2209] Science 2002; 297: 353–356. · DOI · Paper page
  50. Xu PT, Li YJ, Qin XJ, Scherzer CR, Xu H, Schmechel DE et al. Differences in apolipoprotein E3/3 and E4/4 allele-specific gene expression in hippocampus in Alzheimer disease. Neurobiol Dis 2006; 21: 256–275. · DOI · Paper page
  51. Ginsberg SD, Hemby SE, Lee VM, Eberwine JH, Trojanowski JQ . Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Ann Neurol 2000; 48: 77–87. · DOI · Paper page
  52. Palop JJ, Chin J, Mucke L . A network dysfunction perspective on neurodegenerative diseases. Nature 2006; 443: 768–773. · DOI · Paper page

Cited by

Metadata

Authors
Conejero-Goldberg, C., Hyde, T. M., Chen, S., Dreses-Werringloer, U., Herman, M. M., Kleinman, J. E., Davies, P., & Goldberg, T. E.
Venue
Molecular Psychiatry
Published
2010-05-18
Volume
16
Issue
8
Pages
836-847
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
OpenAlex
W2044692031
Cited by
53
References
17
FWCI
3.04
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.